RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease

References

• Valastyan JS, Lindquist S. Mechanisms of protein-folding diseases at a glance. Dis Model Mech. 2014 Jan;7(1):9–14. PMID: 24396149; PMCID: PMC3882043. doi: 10.1242/dmm.013474
   PubMed Web of Science ®Google Scholar
• Doherty J, Baehrecke EH. Life, death and autophagy. Nat Cell Biol. 2018 Oct;20(10):1110–1117. Epub 2018 Sep 17. PMID: 30224761; PMCID: PMC9721133. doi: 10.1038/s41556-018-0201-5
   PubMed Web of Science ®Google Scholar
• Liu X, Green RM. Endoplasmic reticulum stress and liver diseases. Liver Res. 2019 Mar;3(1):55–64. doi: 10.1016/j.livres.2019.01.002
   PubMedGoogle Scholar
• Hwang J, Qi L. Quality control in the endoplasmic reticulum: Crosstalk between ERAD and UPR pathways. Trends Biochem Sci. 2018 Aug;43(8):593–605. Epub 2018 Jun 29. PMID: 30056836; PMCID: PMC6327314. doi: 10.1016/j.tibs.2018.06.005
   PubMed Web of Science ®Google Scholar
• Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 2016 Jan 21;529(7586):326–335. PMID: 26791723. doi: 10.1038/nature17041
   PubMed Web of Science ®Google Scholar
• Kuscuoglu D, Janciauskiene S, Hamesch K, et al. Liver - master and servant of serum proteome. J Hepatol. 2018 Aug;69(2):512–524. Epub 2018 Apr 28. PMID: 29709680. doi: 10.1016/j.jhep.2018.04.018.
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421–446. Erratum in: Nat Rev Drug Discov. 2019 Mar 18;: Erratum in: Nat Rev Drug Discov. 2019 Apr 24;: PMID: 30846871. doi: 10.1038/s41573-019-0017-4
   PubMed Web of Science ®Google Scholar
• Gardin A, Remih K, Gonzales E, et al. Modern therapeutic approaches to liver-related disorders. J Hepatol. 2022 Jun;76(6):1392–1409. PMID: 35589258. doi: 10.1016/j.jhep.2021.12.015.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Aigner A. Therapeutic siRNA: State-of-the-art and future perspectives. BioDrugs. 2022 Sep;36(5):549–571. Epub 2022 Aug 23. PMID: 35997897; PMCID: PMC9396607. doi: 10.1007/s40259-022-00549-3
   PubMed Web of Science ®Google Scholar
• Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol Pathol. 2015 Jan;43(1):78–89. Epub 2014 Nov 9. PMID: 25385330. doi: 10.1177/0192623314551840
   PubMed Web of Science ®Google Scholar
• Kuijper EC, Bergsma AJ, Pijnappel WWMP, et al. Opportunities and challenges for antisense oligonucleotide therapies. J Of Inher Metab Disea. 2021 Jan;44(1):72–87. Epub 2020 Jun 3. PMID: 32391605; PMCID: PMC7891411. doi: 10.1002/jimd.12251
   PubMed Web of Science ®Google Scholar
• Salvador JP, Vilaplana L, Marco MP. Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019 Mar;411(9):1703–1713. Epub 2019 Feb 8. PMID: 30734854. doi: 10.1007/s00216-019-01633-4
   PubMed Web of Science ®Google Scholar
• Lahr WS, Sipe CJ, Skeate JG, et al. CRISPR-Cas9 base editors and their current role in human therapeutics. Cytotherapy. 2023 Mar;25(3):270–276. Epub 2023 Jan 10. PMID: 36635153. doi: 10.1016/j.jcyt.2022.11.013
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493–502. Epub 2021 Jun 26. PMID: 34215024. doi: 10.1056/NEJMoa2107454
   PubMed Web of Science ®Google Scholar
• Southern KW, Murphy J, Sinha IP, et al. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12). CD010966 PMID: 33331662; PMCID: PMC8094390. doi: 10.1002/14651858.CD010966.pub3
   PubMedGoogle Scholar
• Perlmutter DH. Liver injury in α1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest. 2002 Dec;110(11):1579–1583. PMID: 12464659; PMCID: PMC151639. doi: 10.1172/JCI0216787
   PubMed Web of Science ®Google Scholar
• Strnad P, McElvaney NG, Lomas DA, et al. Alpha1-antitrypsin deficiency. N Engl J Med. 2020 Apr 9;382(15): 1443–1455. PMID: 32268028. doi: 10.1056/NEJMra1910234.
   PubMed Web of Science ®Google Scholar
• Patel D, Teckman JH. Alpha-1-antitrypsin deficiency liver disease. Clin Liver Dis. 2018 Nov;22(4):643–655. Epub 2018 Aug 22. PMID: 30266154. doi: 10.1016/j.cld.2018.06.010
   PubMed Web of Science ®Google Scholar
• Chu AS, Chopra KB, Perlmutter DH. Is severe progressive liver disease caused by alpha-1 antitrypsin deficiency more common in children or adults? Liver Transpl. 2016;22(7):886–894. doi: 10.1002/lt.24434
   PubMed Web of Science ®Google Scholar
• Ruiz M, Lacaille F, Berthiller J, et al. Liver disease related to alpha1-antitrypsin deficiency in French children: The DEFI-ALPHA cohort. Liver Int. 2019 Jun;39(6):1136–1146. Epub 2019 Feb 1. PMID: 30589493. doi: 10.1111/liv.14035.
   PubMed Web of Science ®Google Scholar
• Clark VC, Marek G, Liu C, et al. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. J Hepatol. 2018 Dec;69(6):1357–1364. Epub 2018 Aug 21. PMID: 30138687. doi: 10.1016/j.jhep.2018.08.005. .
   PubMed Web of Science ®Google Scholar
• Hamesch K, Mandorfer M, Pereira VM, et al. Liver fibrosis and metabolic alterations in adults with alpha-1-antitrypsin deficiency caused by the Pi*ZZ mutation. Gastroenterology. 2019 Sep;157(3):705–719.e18. Epub 2019 May 20. PMID: 31121167. doi: 10.1053/j.gastro.2019.05.013. .
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900. doi: 10.1164/rccm.168.7.818
   PubMed Web of Science ®Google Scholar
• Greene CM, Marciniak SJ, Teckman J, et al. α1-Antitrypsin deficiency. Nat Rev Dis Primers. 2016;2(1):16051. doi: 10.1038/nrdp.2016.51
   PubMed Web of Science ®Google Scholar
• Tanash HA, Piitulainen E. Liver disease in adults with severe alpha-1-antitrypsin deficiency. J Gastroenterol. 2019;54(6):541–548. doi: 10.1007/s00535-019-01548-y
   PubMed Web of Science ®Google Scholar
• Townsend SA, Edgar RG, Ellis PR, et al. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. Aliment Pharmacol Ther. 2018;47(7):877–885. doi: 10.1111/apt.14537
   PubMed Web of Science ®Google Scholar
• Hamesch K, Strnad P. Non-invasive assessment and management of liver involvement in adults with alpha-1 antitrypsin deficiency. Chronic Obstr Pulm Dis. 2020 Jul;7(3):260–271. PMID: 32697896; PMCID: PMC7857717. doi: 10.15326/jcopdf.7.3.2019.0161
   PubMed Web of Science ®Google Scholar
• Strnad P, Mandorfer M, Choudhury G, et al. ARO-AAT reduces serum and intra-hepatic ZAAT protein in PiZZ alpha-1 antitrypsin deficient patients with liver disease leading to improvements in clinically relevant liver biomarkers. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Nov 13-16, 2020.
   Google Scholar
• Fromme M, Schneider CV, Pereira V, et al. Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut. 2022 Feb;71(2):415–423. Epub 2021 Feb 25. PMID: 33632708. doi: 10.1136/gutjnl-2020-323729
   PubMed Web of Science ®Google Scholar
• Carlson JA, Rogers BB, Sifers RN, et al. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest. 1989 Apr;83(4):1183–1190. PMID: 2784798; PMCID: PMC303805. doi: 10.1172/JCI113999.
   PubMed Web of Science ®Google Scholar
• Teckman JH, An JK, Blomenkamp K, et al. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol. 2004 May;286(5):G851–62. Epub 2003 Dec 18. PMID: 14684378. doi: 10.1152/ajpgi.00175.2003.
   PubMed Web of Science ®Google Scholar
• Wooddell CI, Blomenkamp K, Peterson RM, et al. Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease. JCI Insight. 2020 Jun 18;5(12):e135348. PMID: 32379724; PMCID: PMC7406265. doi: 10.1172/jci.insight.135348.
   PubMed Web of Science ®Google Scholar
• Guo S, Booten SL, Aghajan M, et al. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. J Clin Invest. 2014 Jan;124(1):251–261. Epub 2013 Dec 20. PMID: 24355919; PMCID: PMC3871221. doi: 10.1172/JCI67968.
   PubMed Web of Science ®Google Scholar
• Strnad P, Mandorfer M, Choudhury G, et al. Fazirsiran for liver disease associated with alpha1-antitrypsin deficiency. N Engl J Med. 2022 Aug 11;387(6):514–524. Epub 2022 Jun 25. PMID: 35748699. doi: 10.1056/NEJMoa2205416.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Dec 14;394(10215):2184–2196. Epub 2019 Dec 5. Erratum in: Lancet. 2020 Aug 1;396(10247):312. Erratum in: Lancet. 2021 Jun 19;397(10292):2336. PMID: 31813633. doi: 10.1016/S0140-6736(19)33041-7
   PubMed Web of Science ®Google Scholar
• Gane E, Sjoberg F, Schwabe C, et al. Belcesiran was well tolerated and reduced serum AAT levels in healthy volunteers. Poster presented at: Amer Assoc Study Liver Disease The Liver Meeting, Nov 12, 2021.
   Google Scholar
• Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):668–678. Epub 2022 Mar 7. PMID: 35256455; PMCID: PMC9148983. doi: 10.1136/jnnp-2021-327909
   PubMedGoogle Scholar
• Aimo A, Castiglione V, Rapezzi C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022 Oct;19(10):655–667. Epub 2022 Mar 23. PMID: 35322226. doi: 10.1038/s41569-022-00683-z
   PubMed Web of Science ®Google Scholar
• Brown KM, Nair JK, Janas MM, et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat Biotechnol. 2022 Oct;40(10):1500–1508. Epub 2022 Jun 2. PMID: 35654979. doi: 10.1038/s41587-022-01334-x
   PubMed Web of Science ®Google Scholar
• Mullard A. Antibody-oligonucleotide conjugates enter the clinic. Nat Rev Drug Discov. 2022 Jan;21(1):6–8. PMID: 34903879. doi: 10.1038/d41573-021-00213-5
   PubMed Web of Science ®Google Scholar
• Kumar A, Sidhu J, Goyal A, et al. Alzheimer disease (nursing). 2022 Jun 5. In StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK568805/
   Google Scholar
• Yarns BC, Holiday KA, Carlson DM, et al. Pathophysiology of Alzheimer’s disease. Psychiatr Clin North Am. 2022 Dec;45(4):663–676. Epub 2022 Oct 14. PMID: 36396271. doi: 10.1016/j.psc.2022.07.003.
   PubMed Web of Science ®Google Scholar
• Aduhelm. Prescribing information. Biogen; Feb 2023. Available at: https://www.biogencdn.com/us/aduhelm-pi.pdf [Last accessed 14 Mar 2023].
   Google Scholar
• Leqembi. Prescribing information. Eisai Inc; Jan 2023. Available at: https://www.leqembi.com/-/media/Files/Leqembi/Prescribing-Information.pdf?hash=3d7bf1a2-5db2-4990-8388-81086f415676 [Last accessed 14 Mar 2023].
   Google Scholar
• Singer O, Marr RA, Rockenstein E, et al. Targeting BACE1 with siRnas ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 2005 Oct;8(10):1343–1349. Epub 2005 Aug 28. PMID: 16136043. doi: 10.1038/nn1531
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhu F, Liu Y, et al. Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer’s disease therapy. Sci Adv. 2020 Oct 9;6(41): eabc7031. PMID: 33036977; PMCID: PMC7546706. doi: 10.1126/sciadv.abc7031.
   PubMed Web of Science ®Google Scholar
• McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018 Aug 1;128(8): 3558–3567. Epub 2018 Jul 16. PMID: 30010620; PMCID: PMC6063493. doi: 10.1172/JCI99081.
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022 Sep 22;387(12):1099–1110. PMID: 36129998. doi: 10.1056/NEJMoa2204705
   PubMed Web of Science ®Google Scholar
• Remih K, Amzou S, Strnad P. Alpha1-antitrypsin deficiency: New therapies on the horizon. Curr Opin Pharmacol. 2021 Aug;59:149–156. Epub 2021 Jul 10. PMID: 34256305. doi: 10.1016/j.coph.2021.06.001
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015 Aug;149(2):389–97.e10. Epub 2015 Apr 29. PMID: 25935633; PMCID: PMC4516664. doi: 10.1053/j.gastro.2015.04.043.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Van Natta ML, Clark J, et al. NASH Clinical Research Network (CRN). prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021 Oct 21;385(17):1559–1569. PMID: 34670043; PMCID: PMC8881985. doi: 10.1056/NEJMoa2029349
   PubMed Web of Science ®Google Scholar
• Hui RW, Mak LY, Seto WK, et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Mol Hepatol. 2022 Jul;28(3):408–424. Epub 2022 Feb 17. PMID: 35172540; PMCID: PMC9293617. doi: 10.3350/cmh.2022.0012
   PubMed Web of Science ®Google Scholar
• Ghouse R, Chu A, Wang Y, et al. Mysteries of α1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease. Dis Model Mech. 2014;7(4):411–419. doi: 10.1242/dmm.014092
   PubMed Web of Science ®Google Scholar
• Basak A, Basak S. Protein aggregation and self assembly in health and disease. Current Proteomics. 2022;19(1):4–19. doi: 10.2174/1570164618666210223160742
   Web of Science ®Google Scholar
• Cairns NJ, Lee VM, Trojanowski JQ. The cytoskeleton in neurodegenerative diseases. J Pathol. 2004 Nov;204(4):438–449. PMID: 15495240; PMCID: PMC3011821. doi: 10.1002/path.1650
   PubMed Web of Science ®Google Scholar
• Chapman J, Dogan A. Fibrinogen alpha amyloidosis: insights from proteomics. Expert Rev Proteomics. 2019 Sep;16(9):783–793. Epub 2019 Aug 28. PMID: 31443619; PMCID: PMC6788741. doi: 10.1080/14789450.2019.1659137
   PubMed Web of Science ®Google Scholar
• Eriksson M, Schönland S, Yumlu S, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009 May;11(3):257–262. Epub 2009 Mar 26. PMID: 19324996; PMCID: PMC2671344. doi: 10.2353/jmoldx.2009.080161.
   PubMed Web of Science ®Google Scholar
• Strnad P, Zatloukal K, Stumptner C, et al. Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim Biophys Acta. 2008 Dec;1782(12):764–774. Epub 2008 Sep 6. PMID: 18805482. doi: 10.1016/j.bbadis.2008.08.008.
   PubMed Web of Science ®Google Scholar